Clay-polymer nanocomposites as a novel drug carrier: Synthesis, characterization and controlled release study of Propranolol Hydrochloride

Applied Clay Science

Volumn 80-81, Issue , 2013, Pages 85-92

  Datta, Seema Monika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Antihypertensive drug; Clay polymer nanocomposites; Controlled drug delivery

Indexed keywords

ANTIHYPERTENSIVE DRUGS; CONTROLLED DRUG DELIVERY SYSTEMS; CONTROLLED DRUG RELEASE; DOUBLE EMULSION-SOLVENT EVAPORATION; DRUG ENCAPSULATION EFFICIENCY; DRUG LOADING CAPACITY; LOW MOLECULAR WEIGHT; PH-DEPENDENT RELEASE;

BIODEGRADABLE POLYMERS; CLAY PRODUCTS; CONTROLLED DRUG DELIVERY; COPOLYMERS; DRUG DOSAGE; EMULSIFICATION; LOADING; NANOCOMPOSITES;

DRUG PRODUCTS;

CLAY; COMPOSITE; DRUG; ENCAPSULATION; NANOTECHNOLOGY; POLYMER;

EID: 84880385275     PISSN: 01691317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clay.2013.06.009     Document Type: Article

References (34)

1. Aguzzi C., Cerezo P., Viseras C., Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Applied Clay Science 2007, 36:22-36.
2. Bergaya F., Theng B.K.G., Lagaly G. Handbook of Clay Science 2006, First edition, Elsevier.
3. Chaturvedi K., Umadevi S., Vaghani S. Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation. Scientia Pharmaceutica 2010, 78:927-939.
4. Chen Y., Zhou A., Liu B., Liang J. Tramadol hydrochloride/montmorillonite composite: Preparation and controlled drug release. Applied Clay Science 2010, 49:108-112.
5. Dollery S.C. Therapeutic Drugs 1991, P272-P278. Churchill Livingstone, Edinburgh.
6. Dong Y., Feng S.S. Poly (d, l-lactide-co-lycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:6068-6076.
7. El-Saharty Y.S. Simultaneous high-performance liquid chromatographic assay of furosemide and propranolol HCL and its application in a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 2003, 33:699-709.
8. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009, 30:3297-3306.
9. Gil E.C., Colarte A.I., Bataille B., Pedraz J.L., Rodríguez F., Heinämäki J. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. International Journal of Pharmaceutics 2006, 2006(317):32-39.
10. Iliescu R.I., Andronescu E., Voicu G., Ficai A., Covaliu C.I. Hybrid materials based on montmorillonite and citostatic drugs: preparation and characterization. Applied Clay Science 2011, 52:62-68.
11. Joshi G.V., Kevadiya B.D., Patel H.A., Bajaj H.C., Jasra R.V. Montmorillonite as a drug delivery system: intercalation and in vitro release of Timolol maleate. International Journal of Pharmaceutics 2009, 374:53-57.
12. Joshi G.V., Patel H.A., Kevadiya B.D., Bajaj H.C. Montmorillonite intercalated with Vitamin B1 as drug carrier. Applied Clay Science 2009, 45:248-253.
13. Joshi G.V., Kevadiya B.D., Bajaj H.C. Design and evaluation of controlled drug delivery system of buspirone using inorganic layered clay mineral. Microporous and Mesoporous Materials 2010, 132:526-530.
14. Junping Z., Hongyan W., Hong Z., Lifei X., Kangde Y. Intercalation of amido cationic drug with montmorillonite. Journal of Wuhan University of Technology-Materials Science Edition 2006, 22:250-252.
15. Langer R.S., Kathryn E.U., Cannizzaro S.M., Shakesheff K.M. Polymeric systems for controlled drug release. Chemical Reviews 1999, 99:3181-3198.
16. Lee Y.H., Kuo T.F., Chen B.Y., Feng Y.K., Wen Y.R., Lin W.C., Lin F.H. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomedical Engineering-Applications Basis Communications 2005, 17:72-78.
17. Lin F.H., Lee Y.H., Jian C.H., Wong J.M., Shieh M.J., Wang C.Y. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 2002, 23:1981-1987.
18. Liu J., Boo W.J., Clearfield A., Sue H.J. Intercalation and exfoliation: a review on morphology of polymer nanocomposites reinforced by inorganic layer structures. Materials and Manufacturing Processes 2006, 20:143-151.
19. Mohammadi-Samani S., Adrangui M., Siahi-Shadbad M.R., Nokhodchi A. An approach to controlled-release dosage form of propranolol hydrochloride. Drug Development and Industrial Pharmacy 2000, 26(1):91-94.
20. Mukherjee A., Vishwanatha J.K. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Research 2009, 29:3867-3876.
21. Nunes C.D., Vaz P.D., Fernandes A.C., Ferreira P., Romão C.C., Calhorda M.J. Loading and delivery of sertraline using inorganic micro and mesoporous materials. European Journal of Pharmaceutics and Biopharmaceutics 2007, 66:357-365.
22. Paker-Leggs S., Neau S.H. Pellet characteristics and drug release when the form of propranolol is fixed as moles or mass in formulations for extruded and spheronized Carbopol-containing pellets. International Journal of Pharmaceutics 2009, 369:96-104.
23. Patel J., Patel D., Raval J. Formulation and evaluation of propranolol hydrochloride-loaded carbopol-934p/ethyl cellulose mucoadhesive microspheres. Iranian Journal of Pharmaceutical Research 2010, 9:221-232.
24. Patra C.N., Kumar A.B., Pandit H.K., Singh S.K., Devi M.V. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Acta Pharmaceutica 2007, 57:479-489.
25. Paul D.R., Robeson L.M. Polymer nanotechnology: nanocomposites. Polymer 2008, 49:3187-3204.
26. Rojtanatanya S., Pongjanyakul T. Propranolol-magnesium aluminum silicate complex dispersions and particles: characterization and factors influencing drug release. International Journal of Pharmaceutics 2010, 383(1-2):106-115.
27. Sahoo J., Murthy P.N., Biswal S., Sahoo S.K., Mahapatra A.K. Comparative study of propranolol hydrochloride release from matrix tablets with Kollidon®SR or hydroxy propyl methyl cellulose. AAPS PharmSciTechnol 2008, 9:577-582.
28. Sánchez-Martin M.J., Sánchez-Camazano M., Vicente-Hernández T., Dominguez-Gil A. Interaction of propranolol hydrochloride with montmorillonite. Journal of Pharmacy and Pharmacology 1981, 33:408-410.
29. Sanghavi N.M., Sarawade V.B., Kamath P.R., Bijilani C.P. Matrix tablets of propranolol hydrochloride. Indian Drugs 1998, 26(8):404-407.
30. Schmolka I.R. A review of block polymer surfactants. Journal of American Oil Chemists' society 1977, 54:110-116.
31. Seki Y.S., Kadir Y.C. Adsorption of promethazine hydrochloride with KSF montmorillonite. Adsorption 2006, 12:89.
32. Suresh R., Borkar S.N., Sawant V.A., Shende V.S., Dimble S.K. Nanoclay drug delivery system. International Journal of Pharmaceutical Sciences and Nanotechnology 2010, 3:901-905.
33. Velasco-De-Paola M.V.R., Santoro M.I.R.M., Gai M.N. Dissolution kinetics evaluation of controlled-release tablets containing propranolol hydrochloride. Drug Development and Industrial Pharmacy 1999, 25(4):535-541.
34. Wang X., Wang X.J., Ching C.B. Solubility, metastable zone width and racemic character of Propranolol hydrochloride. Chirality 2002, 14:318-324.